Development and Characterization of Tool Compounds Targeting the Runt Domain╎s interaction With Cbfβ
![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/cae3bb1d-3b59-4765-b8cf-cd18eb28a9b9/bjh12384-fig-0003-m.jpg)
Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library
![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/4f5b7e28-6c4c-4bb6-95af-053ea2c836bf/bjh12384-fig-0002-m.jpg)
Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library
![PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma](https://i1.rgstatic.net/publication/256100894_MEF2B_mutations_lead_to_deregulated_expression_of_the_BCL6_oncogene_in_Diffuse_Large_B_cell_Lymphoma/links/0deec53c530523cce0000000/largepreview.png)
PDF) MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma
![Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/5a636b6e-588f-4e0b-befe-b0554820b177/bjh.2013.162.issue-3.cover.jpg)
Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis - DeAngelo - 2013 - British Journal of Haematology - Wiley Online Library
![PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells](https://i1.rgstatic.net/publication/338086934_A_Novel_Inhibitor_of_STAT5_Signaling_Overcomes_Chemotherapy_Resistance_in_Myeloid_Leukemia_Cells/links/5dfd72224585159aa48d25eb/largepreview.png)
PDF) A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells
![PDF) Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2 PDF) Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2](https://i1.rgstatic.net/publication/259770843_Targeting_STAT5_in_Hematologic_Malignancies_through_Inhibition_of_the_Bromodomain_and_Extra-Terminal_BET_Bromodomain_Protein_BRD2/links/5422d4590cf290c9e3ad626d/largepreview.png)